Avastin Significantly Prolongs Survival of Advanced Lung Cancer Patients
Lung Cancer and Avastin
Avastin (bevacizumab), significantly improves the time patients with advanced non-small cell lung cancer (NSCLC) live without their disease advancing ("progression free survival") when added to cisplatin/gemcitabine chemotherapy, compared with chemotherapy alone. NSCLC is the most common form of the disease and accounts for more than 80 percent of all lung cancers(ii), with histology other than squamous cell as the most common subtype accounting for approximately 60 percent of NSCLC cases. These findings were presented for the first time, today at the 43rd annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
The results of the Avastin in Lung ("AVAiL", BO17704) trial showed that by adding Avastin to a cisplatin/gemcitabine regimen:
- Progression free survival was significantly prolonged by 20 to 30 % over chemotherapy alone
- Tumour response rate was increased by up to 70% compared with